Activity and cellular localization of an oncogenic glioblastoma multiforme-associated EGF receptor mutant possessing a duplicated kinase domain

Oncogene

Volumn 29, Issue 6, 2010, Pages 855-864

  Ozer, B H ^a   Wiepz, G J ^a   Bertics, P J ^a  

^a UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

Author keywords

Constitutive activity; Duplicate kinase domains; EGF receptor (EGFR); Glioblastoma multiforme

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; PHOSPHOTYROSINE;

AMINO TERMINAL SEQUENCE; ANIMAL CELL; ARTICLE; AUTOPHOSPHORYLATION; CARBOXY TERMINAL SEQUENCE; CARCINOGENICITY; CONTROLLED STUDY; DIMERIZATION; ENZYME ACTIVITY; FIBROBLAST; GENETIC TRANSFECTION; GLIOBLASTOMA; IMMUNOFLUORESCENCE; LIGAND BINDING; MOUSE; MUTATION; NONHUMAN; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; PROTEIN PHOSPHORYLATION; PROTEIN PROCESSING; RECEPTOR DOWN REGULATION; RECEPTOR INTRINSIC ACTIVITY; RECEPTOR UPREGULATION;

ANIMALS; ANTIBODIES, MONOCLONAL; BINDING, COMPETITIVE; CELL LINE; ENZYME ACTIVATION; GENE KNOCKOUT TECHNIQUES; GLIOBLASTOMA; LIGANDS; MICE; MUTATION; ONCOGENES; PHOSPHORYLATION; PROTEIN MULTIMERIZATION; PROTEIN STRUCTURE, QUATERNARY; PROTEIN STRUCTURE, TERTIARY; PROTEIN TRANSPORT; RECEPTOR, EPIDERMAL GROWTH FACTOR; TYROSINE;

EID: 76849098862     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2009.385     Document Type: Article

References (34)

1. Anjum R, Blenis J. (2008). The RSK family of kinases: emerging roles in cellular signaling. Nat Rev Mol Cell Biol 9: 747-758.
2. Bertics PJ, Gill GN. (1985). Self-phosphorylation enhances the protein-tyrosine kinase activity of the epidermal growth factor receptor'. J Biol Chem 260: 14642-14647.
3. Blume-Jensen P, Hunter T. (2001). Oncogenic kinase signaling'. Nature 411: 355-365.
4. Bondy ML, Scheurer ME, Malmer B, Barnholtz-Sloan JS, Davis FG, Il'yasova D et al. (2008). Brain tumor epidemiology: consensus from the Brain Tumor Epidemiology Consortium. Cancer 113(Suppl): 1953-1968.
5. Brockmann MA, Ulbricht U, Gruner K, Fillbrandt R, Westphal M, Lamszus K. (2003). Glioblastoma and cerebral microvascular endothelial cell migration in response to tumor-associated growth factors. Neurosurgery 52: 1391-1399; discussion 1399.
6. Chen WS, Lazar CS, Poenie M, Tsien RY, Gill GN, Rosenfeld MG. (1987). Requirement for intrinsic protein tyrosine kinase in the immediate and late actions of the EGF receptor. Nature 328: 820-823.
7. Chu CT, Everiss KD, Wikstrand CJ, Batra SK, Kung HJ, Bigner DD. (1997). Receptor dimerization is not a factor in the signalling activity of a transforming variant epidermal growth factor receptor, (EGFRvIII). Biochem J 324(Part 3): 855-861.
8. Ciesielski MJ, Fenstermaker RA. (2000). Oncogenic epidermal growth factor receptor mutants with tandem duplication: gene structure and effects on receptor function. Oncogene 19: 810-820.
9. Collins VP. (2004). Brain tumours: classification and genes. J Neurol Neurosurg Psychiatry 75(Suppl 2): ii2-ii11.
10. Dummler BA, Hauge C, Silber J, Yntema HG, Kruse LS, Kofoed B et al. (2005). Functional characterization of human RSK4, a new 90-kDa ribosomal S6 kinase, reveals constitutive activation in most cell types. J Biol Chem 280: 13304-13314.
11. Edwin F, Wiepz GJ, Singh R, Peet CR, Chaturvedi D, Bertics PJ et al. (2006). A historical perspective of the epidermal growth factor receptor and related systems. Methods Mol Biol 327: 1-24.
12. Ekstrand AJ, James CD, Cavenee WK, Seliger B, Pettersson RF, Collins VP. (1991). Genes for epidermal growth factor receptor, transforming growth factor alpha, and epidermal growth factor and their expression in human gliomas in vivo. Cancer Res 51: 2164-2172.
13. Fenstermaker RA, Ciesielski MJ, Castiglia GJ. (1998). Tandem duplication of the epidermal growth factor receptor tyrosine kinase and calcium internalization domains in A-172 glioma cells. Oncogene 16: 3435-3443.
14. Fenstermaker RA, Ciesielski MJ. (2007). EGFR intron recombination in human gliomas: inappropriate diversion of V(D)J recombination? Curr Genomics 8: 163-170.
15. Frederick L, Wang XY, Eley G, James CD. (2000). Diversity and frequency of epidermal growth factor receptor mutations in human glioblastomas. Cancer Res 60: 1383-1387.
16. Gill GN, Kawamoto T, Cochet C, Le A, Sato JD, Masui H et al. (1984). Monoclonal anti-epidermal growth factor receptor antibodies which are inhibitors of epidermal growth factor binding and antagonists of epidermal growth factor binding and antagonists of epidermal growth factor-stimulated tyrosine protein kinase activity. J Biol Chem 259: 7755-7760.
17. Grandal MV, Zandi R, Pedersen MW, Willumsen BM, van Deurs B, Poulsen HS. (2007). EGFRvIII escapes down-regulation due to impaired internalization and sorting to lysosomes. Carcinogenesis 28: 1408-1417.
18. Honegger AM, Dull TJ, Felder S, Van Obberghen E, Bellot F, Szapary D et al. (1987). Point mutation at the ATP binding site of EGF receptor abolishes protein-tyrosine kinase activity and alters cellular routing. Cell 51: 199-209.
19. Huang HS, Nagane M, Klingbeil CK, Lin H, Nishikawa R, Ji XD et al. (1997). The enhanced tumorigenic activity of a mutant epidermal growth factor receptor common in human cancers is mediated by threshold levels of constitutive tyrosine phosphoryla-tion and unattenuated signaling. J Biol Chem 272: 2927-2935.
20. Jensen RL. (1998). Growth factor-mediated angiogenesis in the malignant progression of glial tumors: a review. Surg Neurol 49: 189-195; discussion 196.
21. Jiang X, Huang F, Marusyk A, Sorkin A. (2003). Grb2 regulates internalization of EGF receptors through clathrin-coated pits. Mol Biol Cell 14: 858-870.
22. Jorissen RN, Walker F, Pouliot N, Garrett TP, Ward CW, Burgess AW. (2003). Epidermal growth factor receptor: mechanisms of activation and signaling. Exp Cell Res 284: 31-53.
23. Landau M, Fleishman SJ, Ben-Tal N. (2004). A putative mechanism for downregulation of the catalytic activity of the EGF receptor via direct contact between its kinase and C-terminal domains. Structure 12: 2265-2275.
24. Ohgaki H, Kleihues P. (2005). Population-based studies on incidence, survival rates, and genetic alterations in astrocytic and oligoden-droglial gliomas. J Neuropathol Exp Neurol 64: 479-489.
25. Pollack IF, Randall MS, Kristofik MP, Kelly RH, Selker RG, Vertosick Jr FT. (1991). Response of low-passage human malignant gliomas in vitro to stimulation and selective inhibition of growth factor-mediated pathways. J Neurosurg 75: 284-293.
26. Poppleton HM, Wiepz GJ, Bertics PJ, Patel TB. (1999). Modulation of the protein tyrosine kinase activity and autophosphorylation of the epidermal growth factor receptor by its juxtamembrane region. Arch Biochem Biophys 363: 227-236.
27. Riese II DJ, Gallo RM, Settleman J. (2007). Mutational activation of ErbB family receptor tyrosine kinases: insights into mechanisms of signal transduction and tumorigenesis. Bioessays 29: 558-565.
28. Saharinen P, Silvennoinen O. (2002). The pseudokinase domain is required for suppression of basal activity of Jak2 and Jak3 tyrosine kinases and for cytokine-inducible activation of signal transduction. J Biol Chem 277: 47954-47963.
29. Sato JD, Kawamoto T, Le AD, Mendelsohn J, Polikoff J, Sato GH. (1983). Biological effects in vitro of monoclonal antibodies to human epidermal growth factor receptors. Mol Biol Med 1: 511-529.
30. Sihto H, Puputti M, Pulli L, Tynninen O, Koskinen W, Aaltonen LM et al. (2005). Epidermal growth factor receptor domain II, IV, and kinase domain mutations in human solid tumors. J Mol Med 83: 976-983.
31. Smith KJ, Carter PS, Bridges A, Horrocks P, Lewis C, Pettman G et al. (2004). The structure of MSK1 reveals a novel autoinhibitory conformation for a dual kinase protein. Structure 12: 1067-1077.
32. Tang P, Steck PA, Yung WK. (1997). The autocrine loop of TGF-a/ EGFR and brain tumors. J Neurooncol 35: 303-314.
33. Wen PY, Kesari S. (2008). Malignant gliomas in adults. N Engl J Med 359: 492-507.
34. Zhang X, Gureasko J, Shen K, PCole A, Kuriyan J. (2006). An allosteric mechanism for activation of the kinase domain of epidermal growth factor receptor. Cell 125: 1137-1149. (Pubitemid 43866200)